What drug discovery services does 91�Թ� provide?

91�Թ� Discovery supports small-molecule drug discovery from hit identification through hit-to-lead, lead optimisation and candidate selection. Its chemistry-led capabilities include medicinal and synthetic chemistry, computational chemistry, DEL-enabled hit identification, parallel chemistry and compound-library production, supported by specialist partners where programmes require complementary biology, ADME, DMPK or development capabilities.

How does DEL screening fit into 91�Թ� integrated drug discovery?

91�Թ� works with Serengen to incorporate DNA-Encoded Library screening into its wider drug discovery offering. Serengen’s DEL platform provides project-tailored hit identification, after which selected starting points can progress into 91�Թ� hit validation, medicinal chemistry, hit-to-lead and lead optimisation programmes.

Can 91�Թ� support a programme from hit identification to lead optimisation?

Yes. 91�Թ� can support projects across hit identification, hit validation, medicinal chemistry, hit-to-lead and lead optimisation, with additional specialist capabilities coordinated through its partner network when required.

What is Chemspec Europe 2026?

Chemspec Europe is the 39th International Exhibition for Fine and Speciality Chemicals, held in 2026 at Koelnmesse in Germany. It serves as a major meeting point for the chemical industry.

What does 91�Թ� Chemicals offer to companies in the fine and speciality chemicals sector?

91�Թ� Chemicals supports partners with custom synthesis, complex molecule development, route scouting, and scalable chemical solutions for demanding research and industrial applications.

Why is custom synthesis important in fine and speciality chemicals?

Custom synthesis enables companies to access specialized molecules, intermediates, and novel structures that are not readily available off the shelf, helping accelerate innovation and solve technical supply challenges.